LV12994B - Soluble ctla4 mutant molecules and uses thereof - Google Patents

Soluble ctla4 mutant molecules and uses thereof Download PDF

Info

Publication number
LV12994B
LV12994B LVP-02-214A LV020214A LV12994B LV 12994 B LV12994 B LV 12994B LV 020214 A LV020214 A LV 020214A LV 12994 B LV12994 B LV 12994B
Authority
LV
Latvia
Prior art keywords
ctla4
molecule
mutant
soluble
cell
Prior art date
Application number
LVP-02-214A
Other languages
English (en)
Latvian (lv)
Inventor
Robert J Peach
Joseph R Naemura
Peter S Linsley
Jurgen Bajorath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV12994B publication Critical patent/LV12994B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-02-214A 2000-05-26 2002-12-19 Soluble ctla4 mutant molecules and uses thereof LV12994B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
LV12994B true LV12994B (en) 2003-08-20

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-214A LV12994B (en) 2000-05-26 2002-12-19 Soluble ctla4 mutant molecules and uses thereof

Country Status (41)

Country Link
EP (3) EP3029062A1 (Sortimente)
JP (1) JP4328525B2 (Sortimente)
KR (2) KR100889887B1 (Sortimente)
CN (2) CN1309735C (Sortimente)
AR (1) AR031699A1 (Sortimente)
AT (1) ATE271066T1 (Sortimente)
AU (2) AU2001263466C1 (Sortimente)
BE (1) BE2011C041I2 (Sortimente)
BR (1) BRPI0111191B8 (Sortimente)
CA (1) CA2409748C (Sortimente)
CY (2) CY2011019I2 (Sortimente)
CZ (1) CZ304451B6 (Sortimente)
DE (2) DE60104282T2 (Sortimente)
DK (1) DK1248802T3 (Sortimente)
EC (1) ECSP024365A (Sortimente)
EE (2) EE05557B1 (Sortimente)
EG (1) EG24459A (Sortimente)
ES (2) ES2225549T3 (Sortimente)
FR (1) FR11C0053I2 (Sortimente)
GE (1) GEP20053658B (Sortimente)
HK (1) HK1048126B (Sortimente)
HU (2) HU228137B1 (Sortimente)
IL (1) IL152315A (Sortimente)
LT (1) LT5133B (Sortimente)
LU (1) LU91902I2 (Sortimente)
LV (1) LV12994B (Sortimente)
MX (1) MXPA02011534A (Sortimente)
MY (1) MY136113A (Sortimente)
NO (2) NO330797B1 (Sortimente)
PE (1) PE20011338A1 (Sortimente)
PL (1) PL206267B1 (Sortimente)
PT (1) PT1248802E (Sortimente)
RU (1) RU2283847C2 (Sortimente)
SI (1) SI1248802T1 (Sortimente)
SK (1) SK288131B6 (Sortimente)
TR (1) TR200402703T4 (Sortimente)
TW (2) TWI319405B (Sortimente)
UA (1) UA87432C2 (Sortimente)
UY (1) UY26723A1 (Sortimente)
WO (1) WO2001092337A2 (Sortimente)
ZA (1) ZA200208944B (Sortimente)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
SI1372696T1 (sl) * 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
CN100402660C (zh) * 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
SI1969007T1 (sl) * 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2673725C (en) 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
CN103172750B (zh) 2007-11-01 2014-12-10 安斯泰来制药有限公司 免疫抑制性多肽与核酸
CA2739460C (en) 2008-10-02 2019-05-21 Emergent Product Development Seattle, Llc Cd86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN106432474A (zh) * 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
AU2012220861A1 (en) 2011-02-23 2013-09-05 Amgen Inc. Cell culture media for UVC exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
WO2013169338A1 (en) 2012-05-11 2013-11-14 Medimmune, Llc Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN112481337B (zh) 2014-01-13 2024-06-25 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
LT3926051T (lt) 2014-06-04 2024-06-10 Amgen Inc. Žinduolių ląstelių kultūros surinkimo metodai
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
SI3283508T1 (sl) 2015-04-17 2021-09-30 Alpine Immune Sciences, Inc. Imunomodulirajoči proteini z nastavljivimi afinitetami
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
EP3515489B1 (en) * 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
WO2018195402A1 (en) 2017-04-20 2018-10-25 Egenesis, Inc. Methods for generating genetically modified animals
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CA3152665A1 (en) 2019-08-27 2021-03-04 Tonix Pharma Limited Modified tff2 polypeptides
CA3159586A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
EP4168807A1 (en) 2020-06-18 2023-04-26 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
CN116601279A (zh) 2020-07-28 2023-08-15 思进股份有限公司 用于生产多肽的方法和系统
EP4448022A2 (en) 2021-12-16 2024-10-23 Bristol-Myers Squibb Company Detergent for viral inactivation
KR20240167714A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 고역가 항체의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CA2110518C (en) * 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
SI1372696T1 (sl) * 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4

Also Published As

Publication number Publication date
WO2001092337A2 (en) 2001-12-06
LT2002114A (en) 2003-12-29
IL152315A0 (en) 2003-05-29
CA2409748C (en) 2008-09-16
FR11C0053I1 (Sortimente) 2012-01-13
CY2011019I1 (el) 2016-12-14
UA87432C2 (uk) 2009-07-27
MXPA02011534A (es) 2004-08-12
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
KR100889887B1 (ko) 2009-03-24
TWI319405B (en) 2010-01-11
AU2001263466B2 (en) 2006-04-27
SI1248802T1 (en) 2005-02-28
EP1536234B1 (en) 2016-03-16
BR0111191A (pt) 2004-07-06
HK1048126B (en) 2005-03-04
FR11C0053I2 (fr) 2013-01-11
ATE271066T1 (de) 2004-07-15
EE05557B1 (et) 2012-08-15
PE20011338A1 (es) 2002-01-13
GEP20053658B (en) 2005-11-10
AU6346601A (en) 2001-12-11
LT5133B (lt) 2004-05-25
HUS1300012I1 (hu) 2016-08-29
HUP0302201A3 (en) 2010-01-28
DK1248802T3 (da) 2004-11-15
EE05458B1 (et) 2011-08-15
JP2004511213A (ja) 2004-04-15
MY136113A (en) 2008-08-29
BRPI0111191B1 (pt) 2019-12-31
EE200200659A (et) 2004-06-15
RU2283847C2 (ru) 2006-09-20
EG24459A (en) 2009-07-16
EP1248802B1 (en) 2004-07-14
HUP0302201A2 (hu) 2003-10-28
SK15702002A3 (sk) 2004-01-08
ZA200208944B (en) 2004-02-13
CN1309735C (zh) 2007-04-11
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
TW200906857A (en) 2009-02-16
EP1248802B9 (en) 2005-05-11
KR20030009502A (ko) 2003-01-29
NO20025656D0 (no) 2002-11-25
TWI314933B (en) 2009-09-21
BE2011C041I2 (Sortimente) 2020-08-20
NO20025656L (no) 2002-11-25
PL206267B1 (pl) 2010-07-30
UY26723A1 (es) 2001-12-28
KR100895134B1 (ko) 2009-05-04
PL366231A1 (en) 2005-01-24
HK1071931A1 (en) 2005-08-05
AU2001263466C1 (en) 2006-10-26
PT1248802E (pt) 2004-11-30
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
EP1536234A2 (en) 2005-06-01
DE122011100063I1 (de) 2012-06-14
HU228137B1 (en) 2012-12-28
CY1117625T1 (el) 2017-04-26
NO2011027I1 (no) 2012-01-09
BRPI0111191B8 (pt) 2021-05-25
CA2409748A1 (en) 2001-12-06
DE60104282T2 (de) 2005-10-13
NO330797B1 (no) 2011-07-18
DE60104282D1 (de) 2004-08-19
AR031699A1 (es) 2003-10-01
NO2011027I2 (Sortimente) 2011-12-15
CN101255192A (zh) 2008-09-03
CN1441810A (zh) 2003-09-10
IL152315A (en) 2010-04-15
JP4328525B2 (ja) 2009-09-09
ECSP024365A (es) 2003-03-31
ES2571852T3 (es) 2016-05-27
EP1536234A3 (en) 2009-06-03
HK1048126A1 (en) 2003-03-21
EP3029062A1 (en) 2016-06-08
CZ304451B6 (cs) 2014-05-14
ES2225549T3 (es) 2005-03-16
CZ20023892A3 (cs) 2003-09-17
EE201100050A (et) 2011-10-17
TR200402703T4 (tr) 2004-11-22

Similar Documents

Publication Publication Date Title
US10370428B2 (en) Methods of treatment using CTLA4 mutant molecules
EP1248802B1 (en) Soluble ctla4 mutant molecules and uses thereof
AU2006203199B2 (en) Soluble CTLA4 mutant molecules and uses thereof
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF
HK1225393A1 (en) Soluble ctla4 mutant molecules and uses thereof
NZ522031A (en) Uses of soluble CTLA4 (cytotoxic T-lymphocyte-associated protein 4) fusion molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and/or CD86
HK1071931B (en) Soluble ctla4 mutant molecules and uses thereof
NZ542231A (en) Soluble CTLA4 mutant fusion molecules and uses thereof